Immutep Stock Forecast, Price & News

Immutep (NASDAQ:IMMP) Frequently Asked Questions

Is Immutep a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immutep stock.
View analyst ratings for Immutep or view top-rated stocks.

How has Immutep's stock price been impacted by Coronavirus (COVID-19)?

Immutep's stock was trading at $2.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMMP shares have increased by 63.4% and is now trading at $3.48.
View which stocks have been most impacted by COVID-19.

Are investors shorting Immutep?

Immutep saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 213,300 shares, an increase of 110.4% from the October 31st total of 101,400 shares. Based on an average trading volume of 373,700 shares, the short-interest ratio is presently 0.6 days.
View Immutep's Short Interest.

What price target have analysts set for IMMP?

2 brokers have issued 12 month price objectives for Immutep's shares. Their forecasts range from $8.00 to $9.00. On average, they expect Immutep's stock price to reach $8.43 in the next year. This suggests a possible upside of 142.3% from the stock's current price.
View analysts' price targets for Immutep or view top-rated stocks among Wall Street analysts.

Who are Immutep's key executives?

Immutep's management team includes the following people:

• Marc Voigt, Chief Executive Officer, CFO & Executive Director
• Deanne Miller, COO, Secretary & General Counsel
• David Fang, Finance Director & Assistant Secretary
• Frédéric Triebel, Chief Scientific & Medical Officer
• Christian Mueller, Vice President-Strategic Development

Who are some of Immutep's key competitors?

Some companies that are related to Immutep include FibroGen (FGEN), Prometheus Biosciences (RXDX), Innoviva (INVA), MannKind (MNKD), Avidity Biosciences (RNA), Day One Biopharmaceuticals (DAWN), Centessa Pharmaceuticals (CNTA), MacroGenics (MGNX), Vectura Group (VEGPF), Merus (MRUS), Revance Therapeutics (RVNC), Arcturus Therapeutics (ARCT), CannTrust (CNTTF), Seres Therapeutics (MCRB) and Tyra Biosciences (TYRA).
View all of IMMP's competitors.

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

Who are Immutep's major shareholders?

Immutep's stock is owned by a variety of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.49%), Morgan Stanley (1.46%), Renaissance Technologies LLC (0.26%), Verition Fund Management LLC (0.17%), Saturna Capital CORP (0.11%) and Belvedere Trading LLC (0.04%).

Which major investors are selling Immutep stock?

IMMP stock was sold by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, Millennium Management LLC, and Morgan Stanley.

Which major investors are buying Immutep stock?

IMMP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Belvedere Trading LLC, Toroso Investments LLC, Captrust Financial Advisors, Beirne Wealth Consulting Services LLC, Lindbrook Capital LLC, Jump Financial LLC, and Geode Capital Management LLC.

How do I buy shares of Immutep?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $3.48.

How much money does Immutep make?

Immutep has a market capitalization of $297.15 million and generates $2.96 million in revenue each year.

What is Immutep's official website?

The official website for Immutep is www.immutep.com.

Where are Immutep's headquarters?

Immutep is headquartered at LEVEL 12 95 PITT STREET, SYDNEY C3, 2000.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at (128) 315-7003, via email at [email protected], or via fax at 61-2-8569-1880.